MA46570B1 - Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t - Google Patents

Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t

Info

Publication number
MA46570B1
MA46570B1 MA46570A MA46570A MA46570B1 MA 46570 B1 MA46570 B1 MA 46570B1 MA 46570 A MA46570 A MA 46570A MA 46570 A MA46570 A MA 46570A MA 46570 B1 MA46570 B1 MA 46570B1
Authority
MA
Morocco
Prior art keywords
clec
promoting
methods
lymphocytes
reaction
Prior art date
Application number
MA46570A
Other languages
English (en)
Other versions
MA46570A (fr
Inventor
Nicolas Poirier
Bernard Vanhove
Vanessa Gauttier
Elise Chiffoleau
Géraldine TEPPAZ
Original Assignee
Ose Immunotherapeutics
Inst Nat Sante Rech Med
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics, Inst Nat Sante Rech Med, Univ Nantes filed Critical Ose Immunotherapeutics
Publication of MA46570A publication Critical patent/MA46570A/fr
Publication of MA46570B1 publication Critical patent/MA46570B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des méthodes pour favoriser la réponse des lymphocytes t. Les inventeurs ont examiné l'expression et la fonction de clec-1 dans des cd humaines et démontré pour la première fois une expression de surface cellulaire. Ils ont étudié son rôle fonctionnel suite à un déclenchement sur l'orchestration des réponses des lymphocytes t. Les inventeurs ont montré in vitro et in vivo avec des rats déficients en clec-1 et une protéine de fusion clec-1 fc de rat que la perturbation de la signalisation de clec-1 améliore l'activation de th17 in vitro et améliore in vivo l'amorçage des lymphocytes t et l'activation de th17 et th1. En particulier, la présente invention concerne des antagonistes de clec-1 pour favoriser la réponse des lymphocytes t chez un sujet en ayant besoin.
MA46570A 2016-10-21 2017-10-20 Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t MA46570B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306381 2016-10-21
EP17305988 2017-07-24
PCT/EP2017/076911 WO2018073440A1 (fr) 2016-10-21 2017-10-20 Procédés pour favoriser la réponse des lymphocytes t

Publications (2)

Publication Number Publication Date
MA46570A MA46570A (fr) 2021-03-31
MA46570B1 true MA46570B1 (fr) 2021-10-29

Family

ID=60293924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46570A MA46570B1 (fr) 2016-10-21 2017-10-20 Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t

Country Status (20)

Country Link
US (2) US11365257B2 (fr)
EP (2) EP3529262B1 (fr)
JP (2) JP7032396B6 (fr)
KR (1) KR102646708B1 (fr)
CN (1) CN110291102A (fr)
AU (1) AU2017345286B2 (fr)
CA (1) CA3039348C (fr)
CY (1) CY1124584T1 (fr)
DK (1) DK3529262T3 (fr)
ES (1) ES2883678T3 (fr)
HR (1) HRP20211544T1 (fr)
HU (1) HUE056016T2 (fr)
IL (1) IL266111B (fr)
LT (1) LT3529262T (fr)
MA (1) MA46570B1 (fr)
MD (1) MD3529262T2 (fr)
PL (1) PL3529262T3 (fr)
RS (1) RS62463B1 (fr)
SI (1) SI3529262T1 (fr)
WO (1) WO2018073440A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017345286B2 (en) * 2016-10-21 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for promoting T cells response
AU2018229351B2 (en) 2017-02-28 2024-01-04 Vor Biopharma, Inc. Compositions and methods for inhibition of lineage specific proteins
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
CN115151309A (zh) 2019-12-05 2022-10-04 Ose免疫疗法 抗clec-1a抗体及其抗原结合片段
WO2022258714A1 (fr) 2021-06-08 2022-12-15 Ose Immunotherapeutics Anticorps humanisés anti-clec-1a et fragments de liaison à l'antigène de ceux-ci et mimétiques de ceux-ci
WO2023083890A1 (fr) 2021-11-09 2023-05-19 Ose Immunotherapeutics Identification de ligand clec-1 et ses utilisations
WO2024028347A1 (fr) 2022-08-01 2024-02-08 Ose Immunotherapeutics Molécule hybride fc-clec-1 hétérodimère et ses utilisations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
KR960703622A (ko) 1993-07-15 1996-08-31 수잔 포오덴 단백질 티로신 키나아제 억제제의 프로드러그(prodrugs of protein tyrosine kinase inhibitors)
EP0690452A3 (fr) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Mémoire électriquement effaçable et procédé d'effacement
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
EP1206260A4 (fr) 1999-06-30 2002-10-30 Merck & Co Inc Composes inhibiteurs de la src kinase
WO2001000214A1 (fr) 1999-06-30 2001-01-04 Merck & Co., Inc. Composes inhibiteurs de la kinase src
WO2001017995A1 (fr) 1999-09-10 2001-03-15 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
JP3822494B2 (ja) 1999-10-19 2006-09-20 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2004535437A (ja) 2001-06-22 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (fr) 2001-08-30 2003-03-13 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US8246959B1 (en) * 2003-08-01 2012-08-21 University Of Washington Dendritic cell-associated lectin-like molecules, compositions and methods of use
WO2007109571A2 (fr) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Procédés de prédiction et de suivi de la thérapie par l'inhibiteur de la tyrosine kinase
WO2008103947A2 (fr) * 2007-02-23 2008-08-28 Baylor Research Institute Activation de cellules humaines présentant un antigène par l'intermédiaire de clec-6
US20130058957A1 (en) * 2010-02-23 2013-03-07 The University Of Tokyo Dendritic cell immunoreceptor agonist
RU2741120C2 (ru) * 2014-07-21 2021-01-22 Новартис Аг Лечение рака с использованием химерного антигенного рецептора cll-1
AU2017345286B2 (en) 2016-10-21 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for promoting T cells response

Also Published As

Publication number Publication date
PL3529262T3 (pl) 2021-12-27
JP7404418B6 (ja) 2024-01-26
WO2018073440A1 (fr) 2018-04-26
IL266111A (en) 2019-06-30
MD3529262T2 (ro) 2022-01-31
EP3529262A1 (fr) 2019-08-28
US20220281983A1 (en) 2022-09-08
CY1124584T1 (el) 2022-07-22
JP7404418B2 (ja) 2023-12-25
LT3529262T (lt) 2021-11-10
EP3950709A1 (fr) 2022-02-09
JP2020503252A (ja) 2020-01-30
EP3529262B1 (fr) 2021-07-21
US11365257B2 (en) 2022-06-21
KR102646708B1 (ko) 2024-03-12
AU2017345286B2 (en) 2023-08-03
IL266111B (en) 2022-09-01
KR20190068605A (ko) 2019-06-18
CA3039348C (fr) 2023-09-05
CA3039348A1 (fr) 2018-04-26
RS62463B1 (sr) 2021-11-30
ES2883678T3 (es) 2021-12-09
DK3529262T3 (da) 2021-09-20
JP2022065159A (ja) 2022-04-26
HRP20211544T1 (hr) 2022-01-07
AU2017345286A1 (en) 2019-04-18
SI3529262T1 (sl) 2021-12-31
US20190309075A1 (en) 2019-10-10
CN110291102A (zh) 2019-09-27
MA46570A (fr) 2021-03-31
EP3950709B1 (fr) 2024-02-14
JP7032396B6 (ja) 2022-03-22
JP7032396B2 (ja) 2022-03-08
HUE056016T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
MA46570B1 (fr) Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t
Chapman et al. mTOR signaling, Tregs and immune modulation
Eriksson et al. Inhibitory receptors alter natural killer cell interactions with target cells yet allow simultaneous killing of susceptible targets
Ritzel et al. Age-associated resident memory CD8 T cells in the central nervous system are primed to potentiate inflammation after ischemic brain injury
Tennakoon et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis
Zhang et al. Migratory and adhesive cues controlling innate-like lymphocyte surveillance of the pathogen-exposed surface of the lymph node
Hedrich et al. Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human NaV1. 1 mutation
Huh et al. A novel function of adipocytes in lipid antigen presentation to iNKT cells
Le Rond et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells
Marko et al. Age-associated decline in effective immune synapse formation of CD4+ T cells is reversed by vitamin E supplementation
Churina et al. The role of foxp3‐expressing regulatory T cells and T helpers in immunopathogenesis of multidrug resistant pulmonary tuberculosis
Hong et al. TiO2 nanoparticle exposure decreases spermatogenesis via biochemical dysfunctions in the testis of male mice
Marcel et al. Notch1 regulated autophagy controls survival and suppressor activity of activated murine T-regulatory cells
Lohr et al. Role of B7 in T cell tolerance
Guardiola-Serrano et al. Palmitoylation of human FasL modulates its cell death-inducing function
Gregori et al. An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells
Xia et al. TCR and CD28 concomitant stimulation elicits a distinctive calcium response in naive T cells
Garcia Santana et al. Human treg cells are characterized by low/negative CD6 expression
Boldison et al. Tissue-resident exhausted effector memory CD8+ T cells accumulate in the retina during chronic experimental autoimmune uveoretinitis
Brant et al. Role of the aryl hydrocarbon receptor in the immune response profile and development of pathology during Plasmodium berghei Anka infection
Braunstein et al. The role of L-and T-type calcium channels in local and remote calcium responses in rat mesenteric terminal arterioles
Schuldt et al. Cutting edge: Dual TCRα expression poses an autoimmune hazard by limiting regulatory T cell generation
Thedrez et al. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells
Pierau et al. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation
Caton et al. Strength of TCR signal from self‐peptide modulates autoreactive thymocyte deletion and F oxp3+ T reg‐cell formation